Clinical trials: Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
This study is to evaluate the efficacy and safety of atacicept compared to placebo in preventing new flares in subjects with systemic lupus erythematosus (SLE) and to confirm the optimal dose of atacicept for treatment of…
- Trial name
- APRIL-SLE (NCT00624338)
- Testing
- Atacicept 75 mg, Atacicept 150 mg
- Where
- 113 sites in United States, Argentina and 27 more
- Volunteers
- 461 people
- Sponsor
- EMD Serono
Systemic Lupus Erythematosus
A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus
This study will evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and ADA of MIL62 compared with placebo in participants with systemic lupus erythematosus.
- Trial name
- NCT05796206
- Testing
- MIL62
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Systemic Lupus Erythematosus, Scleroderma
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
This is an open lable and single arm study, is designed to evaluate the safety and preliminary efficacy of HN2301 in Autoimmune Disease（AID）
- Conditions
- Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
- Trial name
- SLE，SSc，RA (NCT06801119)
- Testing
- HN2301 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen MagicRNA Biotechnology Co., Ltd
Systemic Lupus Erythematosus
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.
- Trial name
- NCT04976322
- Testing
- Dapirolizumab pegol
- Where
- 123 sites in United States, Argentina and 22 more
- Volunteers
- 760 people
- Sponsor
- UCB Biopharma SRL
Lupus Erythematosus, Lupus Nephritis
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis
- Trial name
- EQUALISE (NCT04128579)
- Testing
- Itolizumab [Bmab 600]
- Where
- 25 sites in United States, India and 1 more
- Volunteers
- 52 people
- Sponsor
- Biocon Limited
Lupus Nephritis
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of CNTO 136 administered intravenously in patients with active, International Society of Nephrology/Renal Pathology Society Class III and IV Lupus Nephritis (LN).
- Trial name
- NCT01273389
- Testing
- CNTO 136
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 25 people
- Sponsor
- Janssen Research & Development, LLC
Systemic Lupus Erythematosus (SLE)
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
This study will evaluate the effect and safety of 626 in patients with SLE
- Trial name
- NCT07185269
- Testing
- 626
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Systemic Lupus Erythematosus
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
This study is a randomized, controlled, phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with systemic lupus erythematosus.
- Trial name
- NCT06857214
- Testing
- GNC-038, Belimumab
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases
This study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants…
- Trial name
- NCT07751315
- Testing
- Ia:QLS2404 very low dose, Ia:QLS2404 low dose, Ia:QLS2404 middle dose
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Healthy, Systemic Lupus Erythematosus
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).
- Conditions
- Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Trial name
- NCT07276958
- Testing
- LY4298445
- Where
- 10 sites in Australia, China and 1 more
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Lupus Nephritis
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
The purpose of this study is to evaluate (Abatacept) for treatment of lupus nephritis when used on a background of Cellcept (mycophenolate) and prednisone (corticosteroids)
- Trial name
- NCT01714817
- Testing
- BMS-188667, Mycophenolate mofetil, Prednisone
- Where
- 149 sites in United States, Argentina and 21 more
- Volunteers
- 695 people
- Sponsor
- Bristol-Myers Squibb
Lupus Nephritis
Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
The purpose of this open-label extension study was to provide treatment with secukinumab for subjects who completed core study treatment in Study CAIN457Q12301 (NCT04181762), and to obtain further data on long-term efficacy…
- Trial name
- NCT05232864
- Testing
- Secukinumab
- Where
- 18 sites in Australia, Brazil and 11 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector
The primary objective of this study is to assess the suitability of the autoinjector for self-administration of belimumab by subjects with SLE in real-life conditions.
- Trial name
- NCT02124798
- Testing
- Belimumab autoinjector
- Where
- 27 sites in United States
- Volunteers
- 95 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants…
- Trial name
- SIRIUS-SLE 1 (NCT05639114)
- Testing
- Ianalumab
- Where
- 135 sites in United States, Argentina and 17 more
- Volunteers
- 436 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erthematosus, Auto Immune Disease
A Study of GR1803 in Systemic Lupus Erythematosus
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
- Trial name
- NCT07348055
- Testing
- GR1803 injection
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Systemic Lupus Erythematosus
Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus
To assess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China.
- Trial name
- NCT06297408
- Testing
- Relma-cel
- Volunteers
- 24 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Lupus
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic lupus erythematosus in male and female adults.
- Trial name
- NCT02265744
- Testing
- BMS-931699
- Where
- 121 sites in United States, Argentina and 21 more
- Volunteers
- 730 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
- Trial name
- NCT03845517
- Testing
- PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg
- Where
- 164 sites in United States, Argentina and 24 more
- Volunteers
- 350 people
- Sponsor
- Pfizer
Systemic Lupus Erythematosus (SLE)
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of YK012 in participants with Moderate to Severe Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT07010835
- Testing
- YK012
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Excyte Biopharma Ltd